Tag Archives: Basel

Invacare introduce their first touch screen remote

BASEL, Switzerland, 23-Aug-2017 — /EuropaWire/ — Global brand leader Invacare brings next generation technology to powerchairs, following extensive trials and consumer-led insights. Touch screen technology is used daily on devices such as smartphones and tablets and thanks to Invacare, this … Read the full press release

3,927 total views, no views today

Basel Committee on Banking Supervision issues FAQs on Basel III countercyclical capital buffer

BASEL, 22-10-2015 — /EuropaWire/ — To promote consistent implementation of the Basel III countercyclical capital buffer, the Basel Committee on Banking Supervision has issued frequently asked questions and other supporting information. The information published today includes a list of all … Read the full press release

Roche acquires California-based Genia Technologies

Basel, 04-6-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA. Genia is developing a single-molecule, semiconductor based, DNA sequencing platform using nanopore … Read the full press release

Roche to invest CHF 800 million to increase production capabilities for its biologic medicines

Investment to help meet rising demand for licensed biologics and expected pipeline growth Basel, Switzerland, 16-10-2013 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced plans to invest 800 million Swiss francs within its global manufacturing network to increase production … Read the full press release

Novartis invites 60 selected students from leading international universities to its headquarters in Switzerland for the International Biotechnology Leadership Camp

The International Biotechnology Leadership Camp (BioCamp) fosters idea exchange with leading scientists as well as entrepreneurship for young talents 60 selected students from leading international universities attend to explore science and innovation at Novartis headquarters in Basel, Switzerland Novartis CEO … Read the full press release

Basilea announced improved operating results in its H1-2013 financials

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data and ceftobiprole regulatory decision in Europe maintained for H2 2013 Significant agreement with BARDA of up to USD 89 million … Read the full press release

The UBS consumption indicator: new cars registrations during H1-2013 was weak in Switzerland

The UBS consumption indicator moved sideways in June. The first half of the year was weak for registrations of new cars. Zurich/Basel, 20-8-2013 — /EuropaWire/ — The UBS consumption indicator remained stable for the most part in June at 1.44 index … Read the full press release

The European Commission approved Novartis drug Lucentis as first effective anti-VEGF treatment for myopic choroidal neovascularization

Lucentis® (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Pivotal trial shows average visual acuity improvement of up to 14 letters at one year with a median of … Read the full press release

Novartis announced US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to its serelaxin (RLX030) for acute heart failure

Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical need If approved, RLX030 has the potential to be the first treatment breakthrough for Acute Heart Failure patients in 20 … Read the full press release

Novartis’s omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with severe form of chronic skin disease CSU

Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four … Read the full press release

UBS AG announced the results of its Annual General Meeting held in May 2013

Zurich / Basel, 4-6-2013 — /europawire.eu/ — At the Annual General Meeting held on May 2, 2013, UBS’s shareholders confirmed in their offices those members of the Board of Directors who had stood for re-election, and voted Reto Francioni onto the Board … Read the full press release

Syngenta 1Q 2013 sales $4.6 billion

Integrated regional sales up 8 percent at constant exchange rates Continuing momentum, growth across all regions High grower profitability supporting ongoing technology adoption Basel, Switzerland, 8-5-2013 — /europawire.eu/ —  In the first quarter of 2013 integrated sales increased by 8 percent … Read the full press release

Syngenta: EU Member States again fail to agree restriction on key crop protection technology

Basel, Switzerland, 7-5-2013 — /europawire.eu/ — Syngenta acknowledged that European Union (EU) Member States for the second time failed to agree on the European Commission’s proposal for a ban on neonicotinoid pesticides. The latest decision should compel the Commission to return to … Read the full press release